SI3607069T1 - Produkti in sestavki - Google Patents
Produkti in sestavkiInfo
- Publication number
- SI3607069T1 SI3607069T1 SI201830836T SI201830836T SI3607069T1 SI 3607069 T1 SI3607069 T1 SI 3607069T1 SI 201830836 T SI201830836 T SI 201830836T SI 201830836 T SI201830836 T SI 201830836T SI 3607069 T1 SI3607069 T1 SI 3607069T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compositions
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165129 | 2017-04-05 | ||
| GBGB1707203.4A GB201707203D0 (en) | 2017-05-05 | 2017-05-05 | Modified positions |
| GBGB1708397.3A GB201708397D0 (en) | 2017-05-25 | 2017-05-25 | Modified positions |
| EP17201352 | 2017-11-13 | ||
| EP18715706.0A EP3607069B1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
| PCT/EP2018/058766 WO2018185241A1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3607069T1 true SI3607069T1 (sl) | 2023-02-28 |
Family
ID=61899311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830836T SI3607069T1 (sl) | 2017-04-05 | 2018-04-05 | Produkti in sestavki |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11015198B2 (sl) |
| EP (2) | EP4219713A3 (sl) |
| JP (3) | JP7155239B2 (sl) |
| CN (1) | CN110520531A (sl) |
| AU (1) | AU2018247925B2 (sl) |
| DK (1) | DK3607069T3 (sl) |
| ES (1) | ES2932831T3 (sl) |
| FI (1) | FI3607069T3 (sl) |
| HR (1) | HRP20221400T1 (sl) |
| HU (1) | HUE061247T2 (sl) |
| IL (2) | IL321221A (sl) |
| LT (1) | LT3607069T (sl) |
| PL (1) | PL3607069T3 (sl) |
| RS (1) | RS63836B1 (sl) |
| SI (1) | SI3607069T1 (sl) |
| WO (1) | WO2018185241A1 (sl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| CA2995110A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| US11753638B2 (en) | 2016-08-12 | 2023-09-12 | University Of Massachusetts | Conjugated oligonucleotides |
| SI3607069T1 (sl) * | 2017-04-05 | 2023-02-28 | Silence Therapeutics Gmbh | Produkti in sestavki |
| HRP20221547T1 (hr) * | 2017-04-05 | 2023-03-03 | Silence Therapeutics Gmbh | Inhibicija tmprss6 posredovana interferencijom rna |
| WO2018185239A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| EP3483269A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| CA3064590A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | Two-tailed self-delivering sirna and related methods |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| EP3598995A1 (en) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
| JP7627042B2 (ja) | 2018-08-23 | 2025-02-05 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| LT3880818T (lt) | 2018-11-13 | 2022-12-27 | Silence Therapeutics Gmbh | Nukleorūgštis, skirta slopinti lpa raišką ląstelėje |
| WO2020150431A1 (en) * | 2019-01-16 | 2020-07-23 | Genzyme Corporation | Serpinc1 irna compositions and methods of use thereof |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| EP3947683A1 (en) * | 2019-04-04 | 2022-02-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| US12024706B2 (en) | 2019-08-09 | 2024-07-02 | University Of Massachusetts | Modified oligonucleotides targeting SNPs |
| US20210115442A1 (en) * | 2019-08-23 | 2021-04-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| US20220288214A1 (en) * | 2019-10-24 | 2022-09-15 | Genevant Sciences Gmbh | Conjugates and methods for treating acromegaly |
| TW202208625A (zh) * | 2020-03-06 | 2022-03-01 | 美商艾利格斯醫療公司 | 經修飾之短干擾核酸(siNA)分子及其用途 |
| WO2022060871A1 (en) | 2020-09-15 | 2022-03-24 | Verve Therapeutics, Inc. | Lipid formulations for gene editing |
| CA3197198A1 (en) | 2020-11-04 | 2022-05-12 | Ute SCHAEPER | Nucleic acids for inhibiting expression of pros1 in a cell |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| AU2022242899A1 (en) * | 2021-03-24 | 2023-11-09 | Atalanta Therapeutics, Inc. | Double-stranded sirna having patterned chemical modifications |
| TW202315943A (zh) | 2021-06-23 | 2023-04-16 | 麻薩諸塞大學 | 用於治療子癇前症及其它血管新生病症的最佳化抗flt1寡核苷酸化合物 |
| EP4493570A2 (en) | 2022-03-16 | 2025-01-22 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| CA3246872A1 (en) | 2022-03-28 | 2023-10-05 | Empirico Inc. | MODIFIED OLIGONUCLEOTIDES |
| CN120981247A (zh) | 2023-03-27 | 2025-11-18 | 赛伦斯治疗有限责任公司 | 用于干细胞移植的化合物和组合物 |
| WO2024245151A1 (zh) * | 2023-05-26 | 2024-12-05 | 维亚臻生物技术（苏州）有限公司 | 一种用于代谢疾病的双链核苷酸化合物及其应用 |
| CN119464281A (zh) * | 2023-08-09 | 2025-02-18 | 北京福元医药股份有限公司 | 抑制DGAT2基因表达的siRNA、siRNA缀合物或其前药和药物组合物及用途 |
| US20250297260A1 (en) | 2024-03-22 | 2025-09-25 | Takeda Pharmaceutical Company Limited | Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| KR20080036650A (ko) | 2005-08-17 | 2008-04-28 | 시르나 쎄러퓨틱스 인코퍼레이티드 | Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자 |
| WO2007112414A2 (en) * | 2006-03-27 | 2007-10-04 | Isis Pharmaceuticals, Inc. | Conjugated double strand compositions for use in gene modulation |
| EP2173358B1 (en) * | 2007-06-22 | 2015-10-21 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| CA2930393C (en) | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AU2009241591A1 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of DSRNA targeting the PCSK9 gene |
| CN102016036B (zh) | 2008-02-11 | 2015-04-08 | 阿克赛医药公司 | 经修饰的RNAi多核苷酸及其用途 |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| WO2012037254A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| WO2012094115A1 (en) | 2010-12-17 | 2012-07-12 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of flt3 genes |
| EP2717882A4 (en) * | 2011-06-06 | 2015-03-25 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION |
| KR102434346B1 (ko) | 2011-06-30 | 2022-08-18 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법 |
| MX391815B (es) * | 2011-11-18 | 2025-03-21 | Alnylam Pharmaceuticals Inc | AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR). |
| KR102853694B1 (ko) | 2011-11-18 | 2025-09-03 | 알닐람 파마슈티칼스 인코포레이티드 | 변형된 ＲＮＡｉ 제제 |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| WO2014089313A1 (en) * | 2012-12-05 | 2014-06-12 | Alnylam Pharmaceuticals | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US9127276B2 (en) * | 2013-05-01 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| KR102365809B1 (ko) * | 2013-05-22 | 2022-02-23 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| US10808246B2 (en) | 2013-07-11 | 2020-10-20 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3151839A4 (en) | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| WO2016085852A1 (en) * | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| EP3271482A4 (en) | 2015-03-17 | 2019-02-13 | Arrowhead Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING THE GENE EXPRESSION OF FACTOR XII |
| HRP20201200T1 (hr) * | 2015-04-03 | 2020-11-13 | University Of Massachusetts | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK |
| EP3277811B1 (en) * | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| EP3332007A4 (en) | 2015-08-07 | 2019-07-17 | Arrowhead Pharmaceuticals, Inc. | RNAi Therapy Against Infection with Hepatitis B Virus |
| CA2995110A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| JOP20210043A1 (ar) | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| CN109526222B (zh) | 2016-06-06 | 2022-04-29 | 箭头药业股份有限公司 | 5’-环膦酸酯修饰核苷酸 |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| TW202436621A (zh) | 2017-01-10 | 2024-09-16 | 美商愛羅海德製藥公司 | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 |
| CA3048661A1 (en) | 2017-01-30 | 2018-08-02 | Arrowhead Pharmaceuticals Inc. | Compositions and methods for inhibition of factor xii gene expression |
| HRP20221547T1 (hr) * | 2017-04-05 | 2023-03-03 | Silence Therapeutics Gmbh | Inhibicija tmprss6 posredovana interferencijom rna |
| SI3607069T1 (sl) | 2017-04-05 | 2023-02-28 | Silence Therapeutics Gmbh | Produkti in sestavki |
| CR20200108A (es) | 2017-09-11 | 2020-06-28 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| MX2020001912A (es) | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| MX2020004897A (es) * | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| LT3880818T (lt) * | 2018-11-13 | 2022-12-27 | Silence Therapeutics Gmbh | Nukleorūgštis, skirta slopinti lpa raišką ląstelėje |
-
2018
- 2018-04-05 SI SI201830836T patent/SI3607069T1/sl unknown
- 2018-04-05 IL IL321221A patent/IL321221A/en unknown
- 2018-04-05 PL PL18715706.0T patent/PL3607069T3/pl unknown
- 2018-04-05 WO PCT/EP2018/058766 patent/WO2018185241A1/en not_active Ceased
- 2018-04-05 CN CN201880021538.7A patent/CN110520531A/zh active Pending
- 2018-04-05 AU AU2018247925A patent/AU2018247925B2/en active Active
- 2018-04-05 JP JP2020504436A patent/JP7155239B2/ja active Active
- 2018-04-05 HR HRP20221400TT patent/HRP20221400T1/hr unknown
- 2018-04-05 EP EP22202294.9A patent/EP4219713A3/en active Pending
- 2018-04-05 RS RS20221162A patent/RS63836B1/sr unknown
- 2018-04-05 FI FIEP18715706.0T patent/FI3607069T3/fi active
- 2018-04-05 ES ES18715706T patent/ES2932831T3/es active Active
- 2018-04-05 EP EP18715706.0A patent/EP3607069B1/en active Active
- 2018-04-05 HU HUE18715706A patent/HUE061247T2/hu unknown
- 2018-04-05 US US16/497,000 patent/US11015198B2/en active Active
- 2018-04-05 LT LTEPPCT/EP2018/058766T patent/LT3607069T/lt unknown
- 2018-04-05 DK DK18715706.0T patent/DK3607069T3/da active
-
2019
- 2019-08-21 IL IL268828A patent/IL268828B2/en unknown
-
2021
- 2021-03-31 US US17/219,265 patent/US12084656B2/en active Active
-
2022
- 2022-10-04 JP JP2022160357A patent/JP7583005B2/ja active Active
-
2024
- 2024-07-26 JP JP2024121088A patent/JP2024147806A/ja active Pending
- 2024-08-07 US US18/797,143 patent/US20250043288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018247925B2 (en) | 2024-06-06 |
| JP7583005B2 (ja) | 2024-11-13 |
| LT3607069T (lt) | 2023-01-10 |
| ES2932831T3 (es) | 2023-01-26 |
| EP3607069A1 (en) | 2020-02-12 |
| JP2024147806A (ja) | 2024-10-16 |
| HRP20221400T1 (hr) | 2023-01-06 |
| CA3057565A1 (en) | 2018-10-11 |
| IL321221A (en) | 2025-07-01 |
| RS63836B1 (sr) | 2023-01-31 |
| JP2020516312A (ja) | 2020-06-11 |
| IL268828B2 (en) | 2025-11-01 |
| JP7155239B2 (ja) | 2022-10-18 |
| IL268828A (en) | 2019-10-31 |
| AU2018247925A1 (en) | 2019-10-03 |
| JP2022173554A (ja) | 2022-11-18 |
| EP3607069B1 (en) | 2022-11-02 |
| US20220090067A1 (en) | 2022-03-24 |
| EP4219713A2 (en) | 2023-08-02 |
| US11015198B2 (en) | 2021-05-25 |
| WO2018185241A1 (en) | 2018-10-11 |
| FI3607069T3 (fi) | 2023-01-13 |
| US20250043288A1 (en) | 2025-02-06 |
| HUE061247T2 (hu) | 2023-06-28 |
| US20200095580A1 (en) | 2020-03-26 |
| DK3607069T3 (da) | 2022-11-21 |
| IL268828B1 (en) | 2025-07-01 |
| PL3607069T3 (pl) | 2023-03-06 |
| CN110520531A (zh) | 2019-11-29 |
| EP4219713A3 (en) | 2023-08-16 |
| US12084656B2 (en) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3607069T1 (sl) | Produkti in sestavki | |
| SI3443009T1 (sl) | Protitelesa proti-TIM-3 in sestavki | |
| PL3628691T3 (pl) | Amfifilowe pochodne polisacharydów i zawierające je kompozycje | |
| DK3478811T3 (da) | Rengøringssammensætninger og anvendelser deraf | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| PL3500255T3 (pl) | Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania | |
| IL255307B (en) | Tpp1 formulations and uses thereon in cln2 disease | |
| IL269576A (en) | products and vehicles | |
| IL269517A (en) | compounds and products | |
| SI3290441T1 (sl) | RGMA-vezavni protein in njegova uporaba | |
| EP3405044A4 (en) | BIOKONSERVATION COMPOSITION FOR FOODSTUFFS AND USES THEREOF | |
| SI3337506T1 (sl) | Kombinacije in njihove uporabe | |
| IL261777B (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| IL290166A (en) | Collagen preparations 7 and its use | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf | |
| DK3266310T3 (da) | Nukleotidsammensætning og anvendelse i fødevare deraf | |
| DK3166960T3 (da) | Lav-substituerede polymyxiner og sammensætninger deraf | |
| EP3655018C0 (en) | COMPOSITION AND NUTRITIONAL SUPPLEMENT PRODUCED THEREFROM | |
| EP3658161A4 (en) | Spent turmeric - methods and compositions thereof | |
| DK3374468T3 (da) | Flamme- eller brandhæmmende midler og fremstilling og anvendelse deraf | |
| EP3305309A4 (en) | ANTICARIOGENIC AGENT AND ANTICARIAC COMPOSITION | |
| DK3099314T3 (da) | Tolerogene sammensætninger og anvendelser deraf |